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Abstract
Background and Objectives Aspirin is widely used for
short-term treatment of pain, fever or colds, but there are
only limited data regarding the safety of this use. To
summarize the available data on this topic, we conducted a
meta-analysis of the published clinical trial literature
regarding the gastrointestinal adverse effects of short-term
use of aspirin in comparison with placebo and other med-
ications commonly used for the same purpose.
Data Sources and Methods An extensive literature search
identified 119,310 articles regarding possible adverse
effects of aspirin, among which 23,131 appeared to possibly
include relevant data. An automated text-mining procedure
was used to score the references for potential relevance for
the meta-analysis. The 3,983 highest-scoring articles were
reviewed individually to identify those with data that could
be included in this analysis. Ultimately, 78 relevant articles
were identified that contained gastrointestinal adverse event
data from clinical trials of aspirin versus placebo or an
active comparator. Odds ratios (ORs) computed using a
Mantel–Haenszel estimator were used to summarize the
comparative effects on dyspepsia, nausea/vomiting, and
abdominal pain, considered separately and also aggregated
as ‘minor gastrointestinal events’. Gastrointestinal bleeds,
ulcers, and perforations were also investigated.
Results Data were obtained regarding 19,829 subjects
(34 % treated with aspirin, 17 % placebo, and 49 % an
active comparator). About half of the aspirin subjects took a
single dose. Aspirin was associated with a higher risk of
minor gastrointestinal events than placebo or active com-
parators: the summary ORs were 1.46 (95 % confidence
interval [CI] 1.15–1.86) and 1.81 (95 % CI 1.61–2.04),
respectively. Ulcers, perforation, and serious bleeding were
not seen after use of aspirin or any of the other interventions.
Conclusions During short-term use, aspirin is associated
with a higher frequency of gastrointestinal complaints than
other medications commonly used for treatment of pain,
colds, and fever. Serious adverse events were not observed
with aspirin or any of the comparators.
1 Background
Aspirin (acetylsalicylic acid), one of the most commonly
used drugs in the USA [1, 2], is commonly purchased over
the counter for short-term treatment of pain, fever, and
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colds. Other nonsteroidal anti-inflammatory drugs (NSA-
IDs) such as ibuprofen and naproxen are also widely used
for these indications. However, with prolonged use, all of
these medications carry a risk of gastrointestinal adverse
effects, including ulceration and bleeding in the luminal
gastrointestinal tract [3–5]. Rarely, these complications can
be life threatening, but even minor adverse effects such as
dyspepsia may be important, since they may discourage
patients from obtaining appropriate treatment.
Despite the common use of these drugs, data regarding
their safety during short-term use in over-the-counter doses
in adults are scattered in the literature and are not well
characterized [6]. We aimed to summarize the gastroin-
testinal toxicity of aspirin in comparison both with placebo
and with other drugs commonly used in this manner, by
conducting a meta-analysis of randomized clinical trial
data bearing on the issue. This report is a companion to a
recent summary using individual subject data on the rela-
tive toxicity of aspirin in short-term trials conducted by
Bayer [7].
2 Methods
On February 20, 2008, we conducted an extensive litera-
ture search of the published medical literature to identify
reports of clinical trials or observational studies comparing
the gastrointestinal toxicity of aspirin with that of placebo
or active comparators. The databases scanned were Med-
line [1950–2008], Embase [1993–2008], Derwent Drug
File [1982–2008], Biosis [1978–2008], Current Contents
[1992–2008], and a Bayer internal bibliographic database
focusing on drug safety [1918–2008]. Search strategies,
tailored to the individual databases, are detailed in
Appendix 1 in the Electronic Supplementary Material. A
total of 119,310 citations (including possible duplicates)
were identified. Articles classified as reviews or meta-
analyses, those written in a language other than English,
and those that were conference abstracts or one-page short
communications were not considered further, as they were
unlikely to provide substantial relevant data. After removal
of evident duplicates, 23,131 reports remained.
2.1 Selection of Reports for Inclusion
in the Meta-Analysis
Since a manual review of each paper we identified was not
feasible, we developed a relevance score, using automated
text mining to grade articles for relevance to our meta-
analysis (Fig. 1). The score was based on the occurrence of
words in article titles, abstracts, and indexing terms. We
searched for five groups of relevant words, related to
(i) study design (e.g., ‘randomized’, ‘cohort’, or ‘meta-
analysis’); (ii) key drug compounds (e.g., ‘aspirin’ or
‘ibuprofen’); (iii) adverse effects (e.g., ‘bleeding’ or ‘dys-
pepsia’); (iv) size of study (i.e., number of subjects); and
(v) drugs NOT used for treatment of pain, inflammatory
conditions, or as a cardioprotective agent. Through repeated
examination of the candidate articles, an extensive list of
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Fig. 1 Selection of publications for inclusion in the meta-analysis
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Appendix 1 in the Electronic Supplementary Material). In
the scoring of each article, the number and places of
occurrence of the terms were counted, generally weighting
the index and title more heavily, and greatly weighting
larger studies. Mention of drugs not used for aspirin-related
conditions lowered the score. The scoring algorithm was
derived in an iterative manner, in which different weighing
factors were tried for each aspect, followed by manual
evaluation of the highest-scoring articles. (Details of the
scoring algorithm are given in Appendix 1 in the Electronic
Supplementary Material).
We aimed to consider in more detail the 4,000 highest-
scoring articles, and we were able to obtain copies of 3,983
of them. These were reviewed by trained physicians at
GGA Software Services (St. Petersburg, Russia), each with
an MD degree and a PhD degree. A paper was considered
‘relevant’ if it summarized a human randomized controlled
trial or epidemiological study, included any usable infor-
mation regarding at least one adverse event during aspirin
treatment, and provided information about the doses of the
active treatments that were studied and the duration of
treatment.
After further elimination of duplicates, there were 3,916
apparently distinct papers. There was a steady decrease in
the percentage of relevant publications across groups of
articles with decreasing relevance scores. There was also a
strong downward trend in the number of adverse events
across papers with decreasing scores; the aggregate number
of events in the 500 lowest-scoring articles was negligible.
Further steps were taken to assess the accuracy of the
selection of reports for inclusion in the meta-analysis. From
the 19,131 articles with lower relevance scores that had not
previously been reviewed in detail, the 616 that included
1,000 or more subjects were screened manually, using the
title and abstract, to ensure that important data were not
missed. None was eligible for inclusion in the meta-anal-
ysis. Among the 2,345 articles with 100–999 subjects,
20 % were similarly reviewed, and only one eligible report
was identified, which contained a total of only six symptom
complaints and thus it was not included in the database.
The original designation of non-relevance was also
checked for the 289 of the 500 papers that had the highest
relevance score but were deemed not relevant. Eight were
judged to be potentially relevant and were included in the
database. In total, there were 805 relevant articles identified
in the pool of the 4,000 highest-scoring reports.
From the relevant articles, data were extracted regarding
details of study design, medications investigated (dose,
duration of treatment and follow-up, etc.), numbers of
subjects, and the numbers of specific events reported. The
counts of subjects at risk of adverse events were taken from
the safety study population (i.e., randomized subjects who
took any study medication), whether or not they provided
any efficacy data. The specific terms used to describe the
adverse events in each of the articles were retained during
the data extraction. These were then grouped into relevant
categories. Dyspepsia, nausea/vomiting, and abdominal
pain were considered separately and also in aggregate as
‘minor gastrointestinal events’. Dyspepsia was taken to
include terms covered by the Medical Dictionary for Reg-
ulatory Activities (MedDRA) preferred term ‘dyspepsia’,
nonspecific (functional) gastrointestinal disorders, eructa-
tion, abdominal/epigastric discomfort, and abdominal ten-
derness but not abdominal pain. Gastrointestinal bleeding
was defined as including all bleeding in the gastrointestinal
tract, ranging from a positive stool test to melena. Clinically
active gastrointestinal ulcers and perforations were also
tabulated, but purely endoscopic findings were not. The
term ‘gastrointestinal events’ was reserved for descriptions
of low specificity reported as a sole safety outcome, as well
as an overall summary of other events considered in the
same publication. Gastrointestinal events that did not match
one of these outcome categories were not considered in the
analysis (e.g. diarrhea, flatulence, constipation, dry mouth).
Data entry was repeated on the 5 % of clinical trial and
observational reports that provided the largest number of
endpoints. Articles with discrepancies were re-reviewed to
reconcile the differences.
The risk of experiencing gastrointestinal adverse events
after short-term treatment with aspirin was assessed using
meta-analytical methods. We did not include observational
studies, as they rarely provided detailed data regarding
dose and duration of treatment, and they did not directly
compare different agents with each other. We included
parallel-design, randomized clinical studies with at least
one aspirin arm at a dose between 325 and 4,000 mg/day
and a treatment duration of at most 10 days. We included
only articles that studied aspirin as monotherapy, i.e., not in
combination with other active agents (e.g., ephedrine).
Vitamin C and caffeine were not considered active com-
ponents. No exclusions were made with regard to blinding,
subject compliance, single vs. multiple dosing, total dos-
ages, or formulations. Crossover trials were excluded
because of concerns regarding unknown carryover effects,
patient dropout between treatment phases, and within-
patient correlations. To avoid including previously reported
data, publications describing Bayer-sponsored studies that
were included in a previous report [7] were also not
included in the current analysis. After these exclusions, a
total of 152 studies from 150 publications were considered.
In some reports, the number of subjects allocated to each
study treatment was stated only as a percentage of an
overall total. The corresponding products were retained in
our database even if this resulted in fractional numbers of
subjects. Calculation of incidence rates of aggregate out-
comes, especially ‘minor gastrointestinal events’, created
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some complexities. To account for the possibility that
individual subjects may have experienced more than one
reported event, we estimated the total event count as the
harmonic mean across the range of all possible event count
values, ranging from the minimum (the largest reported
individual event count) to the maximum (the sum of all
different individual event counts). In formal terms, if ai
was the number of patients affected by adverse event i, the
possible event frequencies ranged between Emin = maxi-
mum of [ai] and Emax = sum of [ai]. In order to assess
whether the harmonic mean presented a reliable risk esti-
mate, two other estimates were calculated in a sensitivity
analysis:
(i) ‘10 % incidence rate’: [Emin ? (Emax - Emin) 9
0.1]/N; and
(ii) ‘90 % incidence rate’: [Emin ? (Emax - Emin) 9
0.9]/N
In all instances, these showed at most minor differences
with the harmonic mean estimate, and thus they are not
presented. Neither the harmonic mean estimates nor the
10 % and 90 % incidence estimates were rounded to
integer values, which resulted in fractional numbers of
patients with some adverse events.
We compared adverse event rates in subjects random-
ized to aspirin with the rates in those treated with placebo,
with any active comparator, or with paracetamol, ibupro-
fen, naproxen, or diclofenac. Odds ratios (ORs) were used
as the measure of the effect, calculated using the Mantel–
Haenszel risk estimator, as it is robust even where few
cases of adverse events occur. A continuity correction that
accounted for the sizes of treatment arms [8] was applied in
case of zero cells in a stratum. Heterogeneity across studies
was assessed using the modified Breslow–Day statistic for
the OR [9, 10], with a P value of B0.10 being considered
an indication of heterogeneity. Studies with no mention of
an adverse event in either treatment arm were not included
in the analysis of that event.
Summary risk differences were also computed, using
Mantel–Haenszel statistics. The absolute rates differed
considerably across studies, presumably varying with the
clinical setting. The risk differences also varied, with
marked heterogeneity in most analyses, indicating that risk
differences were not a suitable scale for summarizing the
data. Consequently, those analyses are not reported here.
For paracetamol, ibuprofen, naproxen, and diclofenac,
overall comparisons and low- and high-dose specific
comparisons were made using the categories listed in the
footnotes to Table 1. In studies with a range of possible
aspirin doses, an average dose was calculated from the
minimum and maximum doses.
A full protocol for the meta-analysis is available from
the corresponding author. Bayer HealthCare (Leverkusen,
Germany) funded the study, and Bayer employees partic-
ipated in this research. All authors assume responsibility
for the integrity of the work.
3 Results
3.1 Studies
Overall, 150 publications describing 152 studies and
48,774 patients were selected; 78 of these with 19,829
subjects provided relevant data for at least one safety
outcome in comparisons of aspirin with placebo or an
active agent (see Table 1 and see Appendix 2 in the
Electronic Supplementary Material). Three studies did not
describe whether subjects and investigators were blinded to
study treatment, but 69 (88 %) were double-blinded. The
most frequently investigated indication was pain—the
Table 1 Characteristics of studies included in the meta-analysis





Drug dosing Single-dose 9,454 57
Multiple-dose 10,375 21
Blinding Single-blind 249 6
Double-blind 19,402 69
Not described 178 3
Indication Post-surgical pain 3,424 25
Dental pain 2,767 19
Healthy volunteer 1,415 13
Pain other than dental, headache,
post-surgical, or cancer
9,603 11
Migraine or tension headache 1,808 5
Antiplatelet effects 305 1
Episiotomy 90 1
Cancer pain 58 1
Cardiovascular disease 239 1
Fever 120 1
Subjects Aspirina 6,712.5 78
Placebo 3,385.5 67
NSAID/analgesicb 9,731 55
NSAID nonsteroidal anti-inflammatory drug
a High-dose aspirin: [1,000 mg/day, low-dose aspirin: B1,000 mg/
day
b Paracetamol: 3,297 subjects in 5 studies (high-dose: [1,000 mg/
day, low-dose: B1,000 mg/day); ibuprofen: 3,430 subjects in 13
studies (high-dose: [400 mg/day, low-dose: B400 mg/day);
naproxen: 211 subjects in 6 studies (high-dose: [500/550 mg/day,
low-dose: B500/550 mg/day); diclofenac: 479 subjects in 5 studies
(high-dose:[25 mg/day, low-dose: B25 mg/day); other active agent:
2,329 subjects in 35 studies
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target condition in 62 studies (79 %). Subjects were aged
between 16 and 75 years; about equal numbers of men and
women were included. A total of 6,712.5 subjects were
allocated aspirin, 3,385.5 placebo, and 9,731 an active
comparator. The aspirin treatment was a single dose in
2,694 subjects (43 %). The daily dose was 500–1,000 mg in
2,874 aspirin-treated subjects (46 %) and 1,500–2,000 mg
in 2,920 subjects (47 %).
3.2 Gastrointestinal Risks
Five studies comparing aspirin with placebo and five
studies comparing aspirin with active comparators reported
data on overall gastrointestinal risks, which were recorded
in 4.2–18.2 % of subjects (Table 2). Aspirin subjects had
higher rates than those allocated placebo (OR 2.12, 95 %
confidence interval [CI] 0.95–4.76) and active comparators
Table 2 Gastrointestinal events in subjects treated with aspirin vs. comparators, all doses
Outcome No. of studies No. of events/no. of subjects [%] OR [95 % CI] P valuea
Aspirin Comparator
Aspirin vs. placebo
Gastrointestinal events 5 23/244 [9.4] 9/213 [4.2] 2.12 [0.95–4.76] 0.55
Minor gastrointestinal events 59 173.3/3,304.5 [5.2] 116/3,170.5 [3.7] 1.46 [1.15–1.86] 0.02
Dyspepsia 22 42.1/1,296 [3.2] 14/1,172 [1.2] 3.17 [1.73–5.82] 0.15
Nausea/vomiting 56 115.7/3,159.5 [3.7] 92.7/2,995.5 [3.1] 1.22 [0.92–1.61] 0.36
Abdominal pain 20 40.7/1,342 [3.0] 19.8/1,233 [1.6] 1.92 [1.12–3.27] 0.47
Aspirin vs. NSAIDs/analgesics
Gastrointestinal events 5 565/3,105 [18.2] 737/6,037 [12.2] 1.61 [1.43–1.82] 0.02
Minor gastrointestinal events 50 609.1/4,888 [12.5] 736.8/9,471 [7.8] 1.81 [1.61–2.04] 0.19
Dyspepsia 26 233.9/3,889 [6.0] 258.3/7,427 [3.5] 1.94 [1.61–2.35] 0.43
Nausea/vomiting 43 206.5/4,693 [4.4] 320.4/9,229 [3.5] 1.37 [1.14–1.64] 0.17
Abdominal pain 20 369.6/3,755 [9.8] 406.9/7,332 [5.6] 1.95 [1.68–2.27] 0.42
Aspirin vs. paracetamol
Gastrointestinal events 3 551/3,039 [18.1] 396/3,023 [13.1] 1.47 [1.28–1.69] 0.31
Minor gastrointestinal events 4 481.4/3,207 [15.0] 305.6/3,195 [9.6] 1.68 [1.44–1.96] 0.31
Dyspepsia 3 184/3,148 [5.8] 120.4/3,133 [3.8] 1.56 [1.23–1.98] 0.31
Nausea/vomiting 4 135.6/3,207 [4.2] 99.9/3,195 [3.1] 1.38 [1.06–1.80] 0.80
Abdominal pain 2 332.3/3,142 [10.6] 201.8/3,125 [6.5] 1.72 [1.43–2.06] 0.37
Aspirin vs. ibuprofen
Gastrointestinal events 1 534/2,890 [18.5] 330/2,869 [11.5] 1.74 [1.50–2.02] ND
Minor gastrointestinal events 13 493.7/3,238 [15.2] 288.1/3,430 [8.4] 2.02 [1.73–2.37] 0.19
Dyspepsia 10 193.5/3,129 [6.2] 100.8/3,320 [3.0] 2.27 [1.76–2.93] 0.73
Nausea/vomiting 11 145.5/3,177 [4.6] 111.1/3,335 [3.3] 1.45 [1.13–1.87] 0.08
Abdominal pain 6 332.9/3,015 [11.0] 183.7/3,026 [6.1] 2.00 [1.65–2.42] 0.34
Aspirin vs. naproxen
Gastrointestinal events 0 ND ND ND ND
Minor gastrointestinal events 6 18.8/187 [10.1] 5.4/211 [2.6] 5.36 [1.95–14.7] 0.15
Dyspepsia 5 9.3/157 [5.9] 4.4/181 [2.4] 3.40 [1.03–11.2] 0.72
Nausea/vomiting 5 8.9/140 [6.3] 1/166 [0.6] 8.84 [1.54–50.8] 0.04
Abdominal pain 4 9.4/151 [6.2] 0/174 [0.0] 68.9 [0.93–5,100] 0.97
Aspirin vs. diclofenac
Gastrointestinal events 1 5/54 [9.3] 5/109 [4.6] 2.12 [0.59–7.67] ND
Minor gastrointestinal events 4 6.3/166 [3.8] 6.8/370 [1.8] 1.31 [0.39–4.46] 0.27
Dyspepsia 1 1/6 [16.7] 2.4/7 [34.3] 0.38 [0.03–5.45] ND
Nausea/vomiting 3 1/106 [0.9] 4/310 [1.3] 0.43 [0.04–4.95] 0.66
Abdominal pain 1 5/60 [8.3] 1/60 [1.7] 5.36 [0.61–47.4] ND
CI confidence interval, ND no data, NSAID nonsteroidal anti-inflammatory drug, OR odds ratio
a P value for heterogeneity
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(OR 1.61 95 % CI 1.43–1.82) [see Table 2 and see
Appendix 3 in the Electronic Supplementary Material].
In 59 studies with 3,304.5 subjects receiving aspirin and
3,170.5 subjects receiving placebo, 5.2 % of aspirin sub-
jects reported a minor gastrointestinal complaint (abdom-
inal pain, dyspepsia, or nausea/vomiting), versus 3.7 % of
placebo subjects. The corresponding summary OR was
1.46 (95 % CI 1.15–1.86) [see Table 2 and see Appendix 3
in the Electronic Supplementary Material]. The ORs
for dyspepsia (3.17, 95 % CI 1.73–5.82) and abdominal
pain (1.92, 95 % CI 1.12–3.27) were also increased
significantly.
Similar findings emerged in comparisons of aspirin with
any active comparator (50 studies with 4,888 and 9,471
subjects, respectively). The pooled risks of minor gastro-
intestinal complaints were 12.5 % in subjects receiving
aspirin and 7.8 % in subjects receiving an NSAID/anal-
gesic. The risks varied modestly across studies of aspirin
versus the different comparators. Abdominal pain tended to
be the most frequent complaint, recorded in 3–11 % of
subjects (see Table 2 and see Appendix 3 in the Electronic
Supplementary Material). Dyspepsia was reported in
3.2–6.2 %, and nausea/vomiting in 3.1–6.3 %. The OR for
aspirin versus any active comparator for minor gastroin-
testinal complaints was 1.81 (95 % CI 1.62–2.04.) The
risks of dyspepsia, nausea and vomiting, and abdominal
pain were each significantly increased for aspirin versus
any active comparator, with ORs between 1.37 and 1.95
(Table 2).
The findings for comparisons of aspirin in any dose with
paracetamol or ibuprofen in any dose were similar to those
for any active comparator, with ORs ranging up to [2.0
(Table 2). Relatively limited data were available for
naproxen and diclofenac; the aspirin ORs ranged from
nonsignificantly reduced risks to nonsignificantly increased
risks for the various endpoints, all with wide CIs.
The data for paracetamol and ibuprofen were dominated
by a single large study, the Paracetamol, Aspirin and Ibu-
profen New Tolerability (PAIN) study [11]. After exclu-
sion of this trial, the numbers of subjects in the analyses
were reduced by about 90 % or more. In this reduced data
set, the ORs for aspirin versus paracetamol were somewhat
lower than the overall estimates, ranging from 0.31 (95 %
CI 0.03–3.38) for dyspepsia in two studies to 3.64 (95 %
CI 0.68–19.54) for abdominal pain in one study. For
comparisons with ibuprofen, the ORs tended to increase
after exclusion of the PAIN study data and generally
retained statistical significance (data not shown).
Overall comparisons of low-dose aspirin (1,000 mg/day
or less) with lower-dose comparators and higher-dose
aspirin ([1,000 mg/day) with higher-dose comparators
were imprecise; most ORs had wide CIs and lacked sta-
tistical significance (data not shown). However, lower-dose
aspirin was associated with significantly more overall
minor gastrointestinal complaints than lower-dose ibupro-
fen (OR 2.67; 95 % CI 1.22–5.84) or naproxen (OR 3.52;
95 % CI 1.01–12.25). Higher-dose aspirin was associated
with significantly more of these complaints than higher-
dose paracetamol (OR 1.68; 95 % CI 1.44–1.97), ibuprofen
(OR 1.99; 95 % CI 1.69–2.33), and naproxen (OR 11.1;
95 % CI 1.74–70.85).
Serious gastrointestinal events were very rare. There
was one perforated appendix in a placebo patient, one case
of ulcerative colitis after placebo treatment, and an ulcer-
ative colitis attack after paracetamol. In one study [12],
gingival bleeding occurred at slightly lower incidence with
aspirin 900 mg (8 %) than with paracetamol 1,000 mg
(13 %), though both rates were higher than those seen with
placebo (3 %). (Statistical significance of the differences
was not reported.) No clinically significant gastrointestinal
bleeds were observed. Two studies each observed that one
aspirin-treated subject had occult blood in stools [13, 14].
4 Discussion
We used a digital data-mining process to identify com-
parative studies of gastrointestinal adverse effects of aspi-
rin and other medications commonly used over the counter
for short-term treatment. After scanning approximately
4,000 articles, we found 150 relevant clinical trials,
including 78 with endpoint data that could be used in our
meta-analysis. Serious gastrointestinal events were very
rare. Although minor gastrointestinal complaints (dyspep-
sia, abdominal pain, and nausea/vomiting) tended to be
uncommon, aspirin was associated with higher risks of
most of them, typically increasing the risk by about
50–100 %. One large study dominated the comparison of
aspirin with paracetamol and ibuprofen; exclusion of its
data from the analyses left the findings more variable but
broadly consistent with the overall results.
Chronic use of NSAIDs is well known to increase the
risk of serious gastrointestinal events such as perforations,
ulcers, and bleeds [3, 4, 15, 16]. We have shown here that
those events are not a concern for short-term use of aspirin
or other drugs commonly used for pain, colds, and fever.
Our main focus was more minor gastrointestinal prob-
lems—subject-reported symptoms, which are inherently
more subjective than serious adverse events. Nausea,
vomiting, and abdominal pain are fairly well defined, but
even with the most careful use, ‘dyspepsia’ can refer to
several different symptom patterns [17, 18]. The ambiguity
in the term naturally carries over to our analysis from the
primary reports we included. However, as far as possible,
we separated dyspepsia from abdominal pain and nausea/
vomiting.
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Previous reports have summarized data regarding gas-
trointestinal symptoms associated with longer-term NSAID
use. In observational studies, aspirin and other NSAIDs
have clearly been associated with dyspepsia [6]. An early
meta-analysis [16] summarized data from NSAID trials
with a treatment duration of four or more days. There was
no statistically significant effect of aspirin or non-aspirin
NSAIDs on dyspepsia, nausea, or abdominal pain in a
random-effects analysis. In a less conservative fixed-effects
analysis, aspirin was associated with an increased risk of
dyspepsia and abdominal pain, and non-aspirin NSAIDs
were associated with an increased risk of dyspepsia. A
more recent meta-analysis summarized data regarding
dyspepsia from randomized, placebo-controlled trials of
non-aspirin NSAIDs used for five or more days [18]. The
association depended on the definition of the endpoint. A
narrow dyspepsia definition (omitting nausea, vomiting,
and other symptoms only tangentially related to epigastric
pain or discomfort) yielded a pooled risk ratio (RR) of 1.36
(95 % CI 1.11–1.67) versus placebo. In analyses using
broader definitions, the RRs were more modest. Aside from
a previous analysis of Bayer-sponsored trials [7], we are
unaware of any previous overview of the adverse effects of
short-term use of any NSAID, including aspirin.
The findings obtained in this meta-analysis are broadly
compatible with those from the meta-analysis of the Bayer
studies [7], which considered aspirin versus placebo, par-
acetamol, or ibuprofen (Table 3). Unfortunately, combined
analysis or even detailed comparison of the two sets of
findings is not possible, because of differences in the def-
initions of the endpoints in the two analyses (see Table 3
footnotes).
Our study utilized a novel data-mining approach to
identify appropriate studies for inclusion in the meta-
analysis. Our literature search identified over 119,000
citations (including possible duplicates) mentioning aspi-
rin; it was obviously not possible to examine each of them
in detail for possible inclusion in our meta-analysis.
Nonetheless, our quality control measures made it clear
that we identified the vast majority of the relevant data, and
this comprehensive approach is a strength of our analysis.
In the end, we included data from 78 studies and almost
22,000 subjects. Consequently, many of our analyses have
considerable statistical precision, and we have stable esti-
mates for the comparison of aspirin with placebo, all active
comparators, paracetamol, or ibuprofen. On the other hand,
our meta-analysis was unavoidably limited by the features
of the studies that were summarized, including possible
lack of compliance, unblinding, and ambiguous definitions
of endpoints. Our findings may also reflect heterogeneity in
effects over the indications for, and duration of, treatment.
Close to half of the subjects who were analyzed received
only a single dose of the study agent.
There are limitations to the interpretation of our data.
Clinical trials of aspirin and other NSAIDs often screen
potential subjects for risks of adverse events, creating low-
risk study populations. Consequently, estimates of absolute
risks of various events may be conservative in comparison
with what might be expected in general use. In interpreting
our data, it should be remembered that as we selected
studies for analysis, we excluded those that reported no
adverse events. This is commonly done, but, other things
being equal, this has the tendency to inflate absolute inci-
dence estimates because it reduces the denominators of
rates without similarly reducing the numerators.
5 Conclusions
In this meta-analysis, serious adverse events were not
observed with short-term use of aspirin or other over-the-
counter medications used for pain, cold, or fever. However,
aspirin conferred a higher risk of minor gastrointestinal
complaints.
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Table 3 Odds ratios (ORs) for aspirin vs. comparators in the current
literature analysis and in Bayer studies









3.2 [1.7–5.8] 1.6 [1.2–2.0] 2.3 [1.8–2.9]
Bayer studies:
‘any dyspepsia’a
1.3 [1.1–1.6] 1.0 [0.7–1.4] 1.5 [0.7–3.2]
Bayer studies:
‘minor dyspepsia’b
1.4 [1.1–1.8] 1.1 [0.8–1.5] 1.8 [0.8–3.9]
Bayer studies:
‘severe dyspepsia’c
0.7 [0.4–1.2] 0.8 [0.3–2.6] 1.4 [0.2–7.8]
Current analysis:
nausea/vomiting
1.2 [0.9–1.6] 1.4 [1.1–1.8] 1.5 [1.1–1.9]
Bayer studies:
‘abdominal pain’d
2.5 [0.3–18.7] 1.9 [0.9–4.0] 1.0 [0.1–6.4]
Current analysis:
abdominal pain
1.7 [1.4–2.1] 1.9 [1.1–3.3] 2.0 [1.7–2.4]
CI confidence interval
a Minor dyspepsia or severe dyspepsia
b Abdominal discomfort, dyspepsia, epigastric discomfort, eructa-
tion, flatulence, gastric dilatation, gastric disorder, hyperchlorhydria,
nausea, stomach discomfort, or abdominal pain upper
c Retching, vomiting
d Abdominal pain, abdominal pain lower
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